Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. The details for the three conferences are:
- The Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place on March 6, 2017. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 3:20 pm ET.
- The 29th Annual ROTH Conference at the Ritz Carlton Hotel in Orange County, California on March 13, 2017. Michael A. Metzger, President and Chief Operating Officer of Syndax, will make a presentation at 4:30 pm PT.
- The Oppenheimer 27th Annual Healthcare Conference at the Westin New York Grand Central on March 22, 2017. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 10:20 am ET.
A live webcast of these presentations can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. For more information on Syndax, please visit www.syndax.com.
Investor Contacts Heather Savelle Argot Partners [email protected] Tel 646.395.3734 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
